{
    "id": "0f89d7be-ad20-46d1-8cce-0cee8ee572cf",
    "indications": {
        "text": "acute infections caused susceptible strains pseudomonas aeruginosa . polymyxin b sulfate choice treatment infections urinary tract , meninges , bloodstream caused susceptible strains ps . aeruginosa . may also used topically subconjunctivally treatment infections eye caused susceptible strains ps . aeruginosa . may indicated serious infections caused susceptible strains following organisms , less potentially toxic drugs ineffective contraindicated : h. influenzae , specifically meningeal infections . escherichia coli , specifically urinary tract infections . aerobacter aerogenes , specifically bacteremia . klebsiella pneumoniae , specifically bacteremia . note : meningeal infections , polymyxin b sulfate administered intrathecal route . reduce development drug-resistant bacteria maintain effectiveness polymyxin b antibacterial drugs , polymyxin b used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "acute infections caused",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_68416"
            }
        ]
    },
    "contraindications": {
        "text": "parenteral intravenous dissolve 500,000 polymyxin b units 300 500 ml solutions parenteral dextrose injection 5 % continuous drip . adults children 15,000 25,000 units/kg body weight/day individuals normal kidney function . amount reduced 15,000 units/kg downward individuals kidney impairment . infusions may given every 12 hours , however , total daily dose must exceed 25,000 units/kg/day . infants infants normal kidney function may receive 40,000 units/kg/day without effects . intramuscular recommended routinely severe pain injection sites , particularly infants children . dissolve 500,000 polymyxin b units 2 ml sterile water injection sodium chloride injection procaine hydrochloride injection 1 % . adults children 25,000 30,000 units/kg/day . reduced presence renal impairment . may divided given either 4 6 hour intervals . infants infants normal kidney function may receive 40,000 units/kg/day without effects . note : doses high 45,000 units/kg/day used limited treating prematures newborn infants sepsis caused ps . aeruginosa . intrathecal treatment choice ps aeruginosa meningitis dissolve 500,000 polymyxin b units 10 ml sodium chloride injection usp 50,000 units per ml unit . adults children 2 years age 50,000 units daily intrathecally 3 4 days , 50,000 units every day least 2 weeks cultures cerebrospinal fluid negative sugar content returned normal . children 2 years age 20,000 units daily , intrathecally 3 4 days 25,000 units every day . continue dose 25,000 units every day least 2 weeks cultures cerebrospinal fluid negative sugar content returned normal . interest safety , solutions parenteral stored refrigeration , unused portions discarded 72 hours . topical ophthalmic dissolve 500,000 polymyxin b units 20 50 ml sterile water injection sodium chloride injection usp 10,000 25,000 units per ml concentration . treatment ps . aeruginosa infections eye , concentration 0.1 percent 0.25 percent ( 10,000 units 25,000 units per ml ) administered 1 3 drops every hour , increasing intervals response indicates . subconjunctival injection 100,000 units/day may used treatment ps . aeruginosa infections cornea conjunctiva . note : avoid total systemic ophthalmic instillation 25,000 units/kg/day .",
        "doid_entities": [
            {
                "text": "meningitis (DOID:9471)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9471"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe pain injection",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_183660"
            }
        ]
    },
    "warningsAndPrecautions": "polymyxin b injection , usp supplied follows : ndc polymyxin b injection , usp package factor 68083-174-10 500,000 units per vial 10 vials per carton storage conditions reconstitution : store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . protect light . retain carton time . reconstitution : product must stored refrigeration , 2\u00b0 8\u00b0c ( 36\u00b0 46\u00b0f ) , unused portion discarded 72 hours . lyophilized . sterile , nonpyrogenic , preservative-free . container closure made natural rubber latex . manufactured : gland pharma limited d.p.pally , dundigal post hyderabad-500043 , india revised : may 2025",
    "adverseReactions": "contraindicated persons prior history hypersensitivity polymyxins .",
    "ingredients": [
        {
            "name": "POLYMYXIN B SULFATE",
            "code": "19371312D4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8310"
        }
    ],
    "organization": "Gland Pharma Limited",
    "name": "POLYMYXIN B",
    "effectiveTime": "20250509",
    "indications_original": "Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa.\n                  \n                  Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa.\n                  \n                  It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated:\n                  \n                  \n                     H. influenzae, specifically meningeal infections.\n                  \n                  \n                     Escherichia coli, specifically urinary tract infections.\n                  \n                  \n                     Aerobacter aerogenes, specifically bacteremia.\n                  \n                  \n                     Klebsiella pneumoniae, specifically bacteremia.\n                  \n                  NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE.\n                  To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications_original": "PARENTERAL\n                  \n                  \n                  \n                     \n                        Intravenous\n                     \n                  \n                  Dissolve 500,000 polymyxin B units in 300 to 500 mL solutions for parenteral dextrose injection 5% for continuous drip.\n                  \n                  \n                     Adults and children\n                  \n                  15,000 to 25,000 units/kg body weight/day in individuals with normal kidney function. This amount should be reduced from 15,000 units/kg downward for individuals with kidney impairment. Infusions may be given every 12 hours, however, the total daily dose must not exceed 25,000 units/kg/day.\n                  \n                  \n                     Infants\n                  \n                  Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.\n                  \n                  \n                     \n                        Intramuscular\n                     \n                  \n                  Not recommended routinely because of severe pain at injection sites, particularly in infants and children. Dissolve 500,000 polymyxin B units in 2 mL sterile water for injection or sodium chloride injection or procaine hydrochloride injection 1%.\n                  \n                  \n                     Adults and children\n                  \n                  25,000 to 30,000 units/kg/day. This should be reduced in the presence of renal impairment. The dosage may be divided and given at either 4 or 6 hour intervals.\n                  \n                  \n                     Infants\n                  \n                  Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.\n                  \n                  \n                     Note\n                     : Doses as high as 45,000 units/kg/day have been used in limited clinical studies in treating prematures and newborn infants for sepsis caused by Ps. aeruginosa.\n                  \n                  \n                     \n                        Intrathecal\n                     \u00a0\n                  \n                     A treatment of choice for \n                     Ps aeruginosa\n                      meningitis\n                  \n                  Dissolve 500,000 polymyxin B units in 10 mL sodium chloride injection USP for 50,000 units per mL dosage unit.\n                  \n                  \n                     Adults and children over 2 years of age\n                  \n                  Dosage is 50,000 units once daily intrathecally for  3 to 4 days, then 50,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.\n                  \n                  \n                     Children under 2 years of age\n                  \n                  20,000 units once daily, intrathecally for 3 to 4 days or 25,000 units once every other day. Continue with a dose of 25,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.\n                  \n                  \n                     IN THE INTEREST OF SAFETY, SOLUTIONS OF PARENTERAL USE SHOULD BE STORED UNDER REFRIGERATION, AND ANY UNUSED PORTIONS SHOULD BE DISCARDED AFTER 72 HOURS.\n                     \n                  \n                  \n                  \n                      TOPICAL\n                  \n                  \n                  \n                     \n                        Ophthalmic\n                     \n                  \n                  Dissolve 500,000 polymyxin B units in 20 to 50 mL sterile water for injection or sodium chloride injection USP for a 10,000 to 25,000 units per mL concentration.\n                  \n                  For the treatment of Ps. aeruginosa infections of the eye, a concentration of 0.1 percent to 0.25 percent (10,000 units to 25,000 units per mL) is administered 1 to 3 drops every hour, increasing the intervals as response indicates.\n                  \n                  Subconjunctival injection of up to 100,000 units/day may be used for the treatment of\u00a0Ps. aeruginosa\u00a0infections of the cornea and conjunctiva. \n                  \n                  \n                     Note: Avoid total systemic and ophthalmic instillation over 25,000 units/kg/day.",
    "warningsAndPrecautions_original": "Polymyxin B for Injection, USP is supplied as follows:\n                  \n                     NDC\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Polymyxin B for Injection, USP\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0Package Factor\n                      68083-174-10\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0500,000 units per vial\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a010 vials per carton\n                  \n                  \n                     Storage Conditions\n                     \n                     Before Reconstitution: Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].\n                  \n                  \n                     Protect from light. Retain in carton until time of use.\n                  \n                  \n                     After Reconstitution: Product must be stored under refrigeration, between 2\u00b0 and 8\u00b0C (36\u00b0 and 46\u00b0F), and any unused portion should be discarded after 72 hours.\n                  \n                  \n                     Lyophilized.\n                  \n                  \n                     \u00a0\n                  \n                  \n                     \u00a0\n                     \n                      Sterile, Nonpyrogenic, Preservative-free.\n                  \n                  \n                     \u00a0\n                     The container closure is not made with natural rubber latex.\n                  \n                  \n                  Manufactured by: Gland Pharma Limited D.P.Pally, Dundigal Post Hyderabad-500043, India\n                  \n                  Revised: May 2025",
    "adverseReactions_original": "This drug is contraindicated in persons with a prior history of hypersensitivity reactions to polymyxins.",
    "drug": [
        {
            "name": "POLYMYXIN B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_59062"
        }
    ]
}